請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25004完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳玉怜 | |
| dc.contributor.author | Fang-Yu Hsieh | en |
| dc.contributor.author | 謝芳瑜 | zh_TW |
| dc.date.accessioned | 2021-06-08T06:00:02Z | - |
| dc.date.copyright | 2007-08-08 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-30 | |
| dc.identifier.citation | Aggarwal, B. B. (2000). Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann Rheum Dis 59 Suppl 1, i6-16.
Baldwin, A. S., Jr. (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14, 649-683. Bevilacqua, M. P., Stengelin, S., Gimbrone, M. A., Jr., and Seed, B. (1989). Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243, 1160-1165. Carlos, T. M., Dobrina, A., Ross, R., and Harlan, J. M. (1990). Multiple receptors on human monocytes are involved in adhesion to cultured human endothelial cells. J Leukoc Biol 48, 451-456. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72, 3666-3670. Chay, C. H., and Pienta, K. J. (2000). Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycocode. J Cell Biochem Suppl Suppl 35, 123-129. Conway, E. M., and Rosenberg, R. D. (1988). Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8, 5588-5592. Esmon, C. T., Esmon, N. L., and Harris, K. W. (1982). Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257, 7944-7947. Esmon, C. T., and Owen, W. G. (1981). Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 78, 2249-2252. Essig, M., Vrtovsnik, F., Nguyen, G., Sraer, J. D., and Friedlander, G. (1998). Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 9, 1377-1388. Fukudome, K., and Esmon, C. T. (1994). Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269, 26486-26491. Gabius, H. J. (1997). Animal lectins. Eur J Biochem 243, 543-576. Geng, Y., Valbracht, J., and Lotz, M. (1996). Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 98, 2425-2430. Goldstein, J. L., and Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature 343, 425-430. Gousseva, N., Kugathasan, K., Chesterman, C. N., and Khachigian, L. M. (2001). Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem 81, 523-534. Grant, M. B., Davis, M. I., Caballero, S., Feoktistov, I., Biaggioni, I., and Belardinelli, L. (2001). Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci 42, 2068-2073. Griendling, K. K., Sorescu, D., Lassegue, B., and Ushio-Fukai, M. (2000). Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20, 2175-2183. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G., Diaz, C., and Lamas, S. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101, 2711-2719. Hillyard, D. Z., Cameron, A. J., McIntyre, A. H., Hadden, M. H., Marshall, H. E., Johnston, N., and Jardine, A. G. (2002). Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol 29, 673-678. Huot, J., Houle, F., Marceau, F., and Landry, J. (1997). Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80, 383-392. Inoue, I., Goto, S., Mizotani, K., Awata, T., Mastunaga, T., Kawai, S., Nakajima, T., Hokari, S., Komoda, T., and Katayama, S. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67, 863-876. Ip, Y. T., and Davis, R. J. (1998). Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol 10, 205-219. Jirik, F. R., Podor, T. J., Hirano, T., Kishimoto, T., Loskutoff, D. J., Carson, D. A., and Lotz, M. (1989). Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 142, 144-147. Karin, M. (1995). The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270, 16483-16486. Koh, K. K. (2000). Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 76, 23-32. Krysiak, R., Okopien, B., and Herman, Z. (2003). Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63, 1821-1854. Kumar, A., Middleton, A., Chambers, T. C., and Mehta, K. D. (1998). Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in interleukin-1beta- and tumor necrosis factor-alpha-induced low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 273, 15742-15748. Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., and Walsh, K. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6, 1004-1010. Kyriakis, J. M., and Avruch, J. (1996). Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18, 567-577. Laufs, U., La Fata, V., Plutzky, J., and Liao, J. K. (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135. Laufs, U., and Liao, J. K. (2000). Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10, 143-148. Lentz, S. R., Tsiang, M., and Sadler, J. E. (1991). Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 77, 542-550. Levine, G. N., Keaney, J. F., Jr., and Vita, J. A. (1995). Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332, 512-521. Li, D., and Mehta, J. L. (2003). 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 10, 17-21. Loetscher, H., Pan, Y. C., Lahm, H. W., Gentz, R., Brockhaus, M., Tabuchi, H., and Lesslauer, W. (1990). Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61, 351-359. Makgoba, M. W., Sanders, M. E., Ginther Luce, G. E., Gugel, E. A., Dustin, M. L., Springer, T. A., and Shaw, S. (1988). Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18, 637-640. Marlin, S. D., and Springer, T. A. (1987). Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51, 813-819. Mody, R., Joshi, S., and Chaney, W. (1995). Use of lectins as diagnostic and therapeutic tools for cancer. J Pharmacol Toxicol Methods 33, 1-10. Mosnier, L. O., and Griffin, J. H. (2006). Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 11, 2381-2399. Mukai, Y., Wang, C. Y., Rikitake, Y., and Liao, J. K. (2007). Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 292, H1937-1942. Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., and Gutierrez, G. (1999). Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946-1949. Nawroth, P. P., Bank, I., Handley, D., Cassimeris, J., Chess, L., and Stern, D. (1986). Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 163, 1363-1375. Ohlin, A. K., and Marlar, R. A. (1995). The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 85, 330-336. Old, L. J. (1985). Tumor necrosis factor (TNF). Science 230, 630-632. Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G., and Lobb, R. (1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59, 1203-1211. Paul, A., Wilson, S., Belham, C. M., Robinson, C. J., Scott, P. H., Gould, G. W., and Plevin, R. (1997). Stress-activated protein kinases: activation, regulation and function. Cell Signal 9, 403-410. Pober, J. S. (1987). Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Ciba Found Symp 131, 170-184. Read, M. A., Whitley, M. Z., Gupta, S., Pierce, J. W., Best, J., Davis, R. J., and Collins, T. (1997). Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 272, 2753-2761. Rice, G. E., and Bevilacqua, M. P. (1989). An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246, 1303-1306. Roebuck, K. A., and Finnegan, A. (1999). Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 66, 876-888. Rosenson, R. S., and Tangney, C. C. (1998). Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Jama 279, 1643-1650. Ross, R. (1999). Atherosclerosis--an inflammatory disease. N Engl J Med 340, 115-126. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H., and et al. (1990). Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61, 361-370. Shi, J., Wang, J., Zheng, H., Ling, W., Joseph, J., Li, D., Mehta, J. L., Ponnappan, U., Lin, P., Fink, L. M., and Hauer-Jensen, M. (2003). Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14, 575-585. Shrikant, P., Chung, I. Y., Ballestas, M. E., and Benveniste, E. N. (1994). Regulation of intercellular adhesion molecule-1 gene expression by tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma in astrocytes. J Neuroimmunol 51, 209-220. Singh, R., Wang, B., Shirvaikar, A., Khan, S., Kamat, S., Schelling, J. R., Konieczkowski, M., and Sedor, J. R. (1999). The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J Clin Invest 103, 1561-1570. Skaletz-Rorowski, A., Muller, J. G., Kroke, A., Waltenberger, J., Pulawski, E., Pinkernell, K., and Breithardt, G. (2001). Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition. Eur J Cell Biol 80, 207-212. Smith, J. G., Magee, D. M., Williams, D. M., and Graybill, J. R. (1990). Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis 162, 1349-1353. Sohn, R. H., Deming, C. B., Johns, D. C., Champion, H. C., Bian, C., Gardner, K., and Rade, J. J. (2005). Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 105, 3910-3917. Speiser, W., Kapiotis, S., Kopp, C. W., Simonitsch, I., Jilma, B., Jansen, B., Exner, M., and Chott, A. (2001). Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 85, 362-367. Suzuki, K., Nishioka, J., Hayashi, T., and Kosaka, Y. (1988). Functionally active thrombomodulin is present in human platelets. J Biochem (Tokyo) 104, 628-632. Takemoto, M., and Liao, J. K. (2001). Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21, 1712-1719. Tamanini, A., Rolfini, R., Nicolis, E., Melotti, P., and Cabrini, G. (2003). MAP kinases and NF-kappaB collaborate to induce ICAM-1 gene expression in the early phase of adenovirus infection. Virology 307, 228-242. Tamura, D. Y., Moore, E. E., Johnson, J. L., Zallen, G., Aiboshi, J., and Silliman, C. C. (1998). p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery 124, 403-407; discussion 408. Taylor, R. G., and Lewis, J. C. (1986). Endothelial cell proliferation and monocyte adhesion to atherosclerotic lesions of white carneau pigeons. Am J Pathol 125, 152-160. Tristano, A. G., and Fuller, K. (2006). Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6, 1833-1846. Undas, A., Celinska-Lowenhoff, M., Kaczor, M., and Musial, J. (2004). New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 91, 1065-1077. Van Aelst, L., and D'Souza-Schorey, C. (1997). Rho GTPases and signaling networks. Genes Dev 11, 2295-2322. Wang, H. R., Li, J. J., Huang, C. X., and Jiang, H. (2005). Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353, 53-60. Waugh, J. M., Li-Hawkins, J., Yuksel, E., Kuo, M. D., Cifra, P. N., Hilfiker, P. R., Geske, R., Chawla, M., Thomas, J., Shenaq, S. M., et al. (2000). Thrombomodulin overexpression to limit neointima formation. Circulation 102, 332-337. Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., and Hommel, U. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7, 687-692. Zapolska-Downar, D., Zapolski-Downar, A., Markiewski, M., Ciechanowicz, A., Kaczmarczyk, M., and Naruszewicz, M. (2001). Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Atherosclerosis 155, 123-130. Zhang, F., Yu, W., Hargrove, J. L., Greenspan, P., Dean, R. G., Taylor, E. W., and Hartle, D. K. (2002). Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis 161, 381-386. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25004 | - |
| dc.description.abstract | Atorvastatin (Lipitor®) 是三氫氧基三甲基穀胱胺基輔酶還原酶的抑制劑(HMG-CoA reductase inhibitor)，除了能夠降低血漿中低密度脂蛋白與膽固醇的濃度外，亦具有多項功能，在臨床上常被用來治療心血管疾病。血栓調節蛋白(thrombomodulin, TM)是位於血管內皮細胞上的醣蛋白，可與血液中的血栓蛋白結合，進而抑制血液凝血機制。在本實驗主要探討以atorvastatin處理，是否會影響TNF-α刺激人類主動脈內皮細胞表現TM與ICAM-1的表現之影響以及其相關機制。
實驗結果顯示，以atorvastatin處理人類主動脈內皮細胞之後，可回復受到TNF-α所抑制的TM表現，同時與控制組相比較，TM的表現有增加的趨勢；使用共軛焦顯微鏡進行觀察，以atorvastatin處理組，其細胞質內的TM表現有增加的趨勢。另外atorvastatin也可減少由TNF-α所誘發的細胞間黏附分子-1(Intercellular adhesion molecule-1, ICAM-1)表現，與控制組相比，ICAM-1的表現亦顯著受到抑制。以TNF-α刺激內皮細胞，可以誘導JNK (c-Jun N-terminal kinases)、ERK (extracellular signal-regulated protein kinases)及p38 MAPK (p38 mitogen activated protein kinase)的磷酸化，比較控制組與atorvastatin處理組發現atorvastatin能同時抑制JNK、ERK及p38MAPKs的活化；而加入ERK、JNK及p38MAPK抑制劑不僅能增加TM的表現，同時也抑制ICAM-1的表現。若加入抑制劑後再以atorvastatin處理，加入ERK inhibitor後，TM的表現增加但ICAM-1的表現受到抑制；而加入JNK及p38MAPK inhibitor後，其TM表現與控制組相比並無明顯差別，然而ICAM-1表現卻會受到抑制。此外，進一步以adhesion assay來觀察人類主動脈內皮細胞與單核球的黏附情形，發現給予atorvastatin處理，單核球黏附的情形有減少的趨勢，若以anti-TM抗體處理細胞，則單核球黏附內皮細胞的情形大量增加。以 NF-κB的p65抗體進行免疫螢光染色後，發現atorvastatin能減少受到TNF-α所活化而進入細胞核的NF-κB p65蛋白。 由以上實驗結果，可推論TM與ICAM-1之表現呈現負相關的情形，而atorvastatin可同時經由ERK、JNK和p38調控ICAM-1的表現，並經由ERK調控TM的表現；因此atorvastatin可以藉由增加TM表現，減少ICAM-1表現，並抑制NF-κB的活化，保護血管內皮細胞，減少受到發炎因子刺激。 | zh_TW |
| dc.description.abstract | Expression of functionally active thrombomodulin (TM) on endothelial cells is critical for vascular thromboresistance. The 3-hydroxyl-3-methyl coenzyme A reductase inhibitor, atorvastatin (Lipitor®), can protect the vasculature that is independent on its lipid-lowering activity. In the present study, the effects of atorvastatin on the expression of TM and ICAM-1 and their underlying mechanisms in human aortic endothelial cells (HAECs) with or without tumor necrosis-alpha (TNF-α) treatment were investigated. Atorvastatin upregulated TM levels in both control and (TNF-α) treatment were investigated. Atorvastatin upregulated TM levels in both control and TNFα-treated HAECs by Western blotting and by immunohistochemical staining. In contrast, atorvastatin decreased ICAM-1 expression in both control and TNFα-treated HAECs by Western blotting as well as the adherence of monocytes to TNFα-treated HAECs. Atorvastatin attenuated the phosphorylation of ERK, JNK and p38 MAPKs with or without TNF-α treatment. Atorvastatin upregulated the expression of TM with pretreatment of ERK inhibitor but not with JNK and p38MAPK inhibitors.
Atorvastatin downregulated the expression of ICAM-1 with ERK, JNK and p38MAPK inhibitors. Atorvastatin also inhibited the translocation of p65 subunit of NF-κB from the cytosol to the nucleus. These results suggested that atorvastatin mediated the increase of TM expression and the decrease of ICAM-1 expression which may contribute the beneficial effects to endothelial functions. The increase in endothelial TM activity and the decrease of ICAM-1 in response to atorvastatin constitute the novel pleiotropic effects of the commonly used compound and may be of clinical significance in diseases in which deficient endothelial TM plays a pathophysiological role. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T06:00:02Z (GMT). No. of bitstreams: 1 ntu-96-R94446011-1.pdf: 2125389 bytes, checksum: dd0aee2d1758ca75bbaab224e50ee2ca (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 中文摘要 2
英文摘要 4 緒論 5 一、前言 5 二、動脈硬化(atherosclerosis)與內皮細胞(endothelial cells)的關係 5 三、動脈硬化(atherosclerosis)與腫瘤壞死因子(TNF-α)的關係 7 四、血栓調節蛋白(Thrombomodulin, TM) 8 五、動脈硬化與細胞黏附分子的關係 9 六、動脈硬化和Mitogen Activated Protein Kinase (MAPK)的關係 11 七、動脈硬化與轉錄因子NF-κB的關係 12 八、三氫氧基三甲基穀胱胺基輔酶A還原酶抑制劑 (Statins) 13 九、研究目的 15 貳、材料與方法 16 叁、實驗結果 28 肆、討論與結論 36 伍、附圖 40 陸、參考文獻 69 | |
| dc.language.iso | zh-TW | |
| dc.subject | 人類主動脈內皮細胞 | zh_TW |
| dc.subject | 血栓調節蛋白 | zh_TW |
| dc.subject | human aortic endothelial cells | en |
| dc.subject | atorvastatin | en |
| dc.subject | thrombomodulin | en |
| dc.title | 探討atorvastatin對人類主動脈內皮細胞中血栓調節蛋白的表現及其相關機制 | zh_TW |
| dc.title | The effects of atorvastatin on thrombomodulin expression and the related mechanisms in human aortic endothelial cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 王淑美,姜安娜 | |
| dc.subject.keyword | 血栓調節蛋白,人類主動脈內皮細胞, | zh_TW |
| dc.subject.keyword | thrombomodulin,human aortic endothelial cells,atorvastatin, | en |
| dc.relation.page | 77 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2007-07-31 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 解剖學暨生物細胞學研究所 | zh_TW |
| 顯示於系所單位： | 解剖學暨細胞生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 2.08 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。